At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
Busulfan, Fludarabine, Cytoxandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Dec 17, 2008·Updated Feb 16, 2015
In Brief
A Phase 2 clinical trial evaluating Busulfan, Fludarabine, Cytoxan for Lymphoma and 3 related conditions. Completed, enrolled 92 participants across 3 sites.
Detailed Summary
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartMay 2009
Primary CompletionDec 2011
TodayJul 2026
First PostedDec 17, 2008
Enrollment StartMay 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 17.5 years ago
Interventions
Busulfan, Fludarabine, Cytoxandrug
Busulfan once a day for 4 days Fludarabine once a day for 4 days Bone marrow transplant Cytoxan two doses